Abbott Gains CE Mark for Pacemaker

Abbott’s rhythm treatment segment attributed the 7.5% organic sales rise in the Q1 due to Aveir. Following Aveir’s U.S. approval last year, the CEO Robert Ford stated during an April financial call that the company “rapidly captured market share” within the single-chamber pacemaker category.

According to Ford, Abbott presently holds half of the market share in the United States for single-chamber pacemakers. Right now, the business wants to increase the dual-chamber device’s revenue. The CEO of Abbott stated that the company saw “a nice… ramp-up over this first quarter” and that additional growth may be achievable when more doctors get Aveir DR training.

“It’s a completely different procedure … If you think about how these devices have been implanted, this is probably the first time in like 30 years you have a real meaningful change on how this is done,” Ford stated.

He continued: “Our focus here is really getting great clinical results, a real thoughtful approach here about opening new centers and training.”